

# Marjorie G Zauderer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5319752/publications.pdf>

Version: 2024-02-01

49  
papers

3,501  
citations

201674

27  
h-index

206112

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

4449  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.	1.1	24
2	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	2.0	15
3	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
4	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	2.5	10
5	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	10.7	49
6	Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614.	3.7	2
7	The therapeutic implications of the genomic analysis of malignant pleural mesothelioma. <i>Nature Communications</i> , 2021, 12, 1819.	12.8	3
8	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-“PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	9.4	222
9	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	12.3	23
10	Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, .	2.4	3
11	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.	5.5	65
12	Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. <i>American Journal of Industrial Medicine</i> , 2020, 63, 105-114.	2.1	12
13	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	329.8	306
14	Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440.	7.0	7
15	Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. <i>Genome Medicine</i> , 2019, 11, 18.	8.2	36
16	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
17	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	9.4	422
18	Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. <i>International Journal of Cancer</i> , 2017, 140, 1976-1984.	5.1	35

#	ARTICLE	IF	CITATIONS
19	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses $\text{NF-}\kappa\text{B}$ -Driven Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1693-1704.	4.1	31
20	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.8	19
21	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.	1.1	53
22	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	7.0	48
23	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345.	0.2	1
24	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.	1.8	31
25	Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. <i>Lancet Oncology</i> , The, 2016, 17, e43-e44.	10.7	28
26	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	1.6	154
27	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive $\text{ALK}$ -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	3.7	119
28	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	7.0	103
29	Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 249-255.	1.1	53
30	A new standard for malignant pleural mesothelioma. <i>Lancet</i> , The, 2016, 387, 1352-1354.	13.7	14
31	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.	2.5	17
32	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172.	0.4	11
33	A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1272-1277.	1.1	33
34	Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. <i>Lung Cancer</i> , 2014, 86, 237-240.	2.0	47
35	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.8	55
36	Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 84, 271-274.	2.0	101

#	ARTICLE	IF	CITATIONS
37	Toxicity of initial chemotherapy in older patients with lung cancers. <i>Journal of Geriatric Oncology</i> , 2013, 4, 64-70.	1.0	18
38	Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1430-1433.	1.1	81
39	New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment. <i>Clinical Cancer Research</i> , 2012, 18, 4485-4490.	7.0	77
40	Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1278-1283.	0.8	142
41	Novel and Targeted Therapies. , 2012, , 95-101.		0
42	Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 487-90.	1.7	9
43	Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 42-47.	4.9	22
44	The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 163-172.	3.0	37
45	Leptomeningeal Metastases from Small Cell Lung Cancer Responsive to Temozolomide Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1716-1717.	1.1	5
46	Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 205-210.	2.5	48
47	Developing a cancer-specific geriatric assessment. <i>Cancer</i> , 2005, 104, 1998-2005.	4.1	541
48	Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 151-156.	2.5	47
49	Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Drugs and Aging</i> , 2005, 22, 709-715.	2.7	13